This document provides information about the drug Wedica (Trelagliptin). It is a DPP-4 inhibitor used to treat Type 2 diabetes. Wedica comes as 50 mg and 100 mg tablets and is administered once weekly by mouth to adults. It works by increasing incretin levels, inhibiting glucagon release, and increasing insulin secretion to lower blood glucose levels by inhibiting the DPP-4 enzyme. Wedica offers a unique once weekly dosing compared to other DPP-4 inhibitors which are once daily. It also has a lesser risk of hypoglycemic events and is more potent than other DPP-4 inhibitors like Alogliptin and Sitagliptin. The document provides information on

1. WEDICA
TRELAGLIPTIN
Presented By:
Faruk Hossain
Sr. Executive
Beacon Medicare Limited
WeChat/WhatsApp:
+8801717678894
Email:
faruk@beaconmedicare.com.bd

3. Brand Name: Wedica
Generic Name: Trelagliptin succinate
Therapeutic Class: DPP-4 Inhibitor
Dosage Form: Tablet
Strength: 50 mg & 100 mg.
Packaging- Wedica 50 Tablet : Each commercial box contains 20
tablets (2x10’s) in Alu-Alu blister pack.
Wedica 100 Tablet : Each commercial box contains 16 tablets (2x8’s)
in Alu-Alu blister pack.

4. Mode of action
Increases incretin levels which inhibit glucagon release,
which in turn increases insulin secretion,
Decreases blood glucose levels.
Inhibit DPP-4 enzyme

5. INDICATION
Indicated for Type 2 diabetes mellitus, When the
first line treatment of Metformin is not achieving
the expected Glycemic goals.

6. DOSAGE & ADMINISTRATION
100 mg of Trelagliptin is administered to adults once weekly by mouth.
Cautions Related to Methods and Dose
For patients with moderate kidney function disease, given that blood drug concentration will
elevate due to delayed elimination, reduce dosage with reference to the chart below.

7. 1) Patients with moderate kidney function disorder
2) Patients undergoing treatment with sulfonylurea drugs or insulin
medication there are reports of severe hypotension with use in
combination with other DPP-4 inhibitors
3) Hypopituitarism or hypoadrenalism
4) Malnutrition, starvation, irregular eating patterns, insufficient eating,
or hyposthenia
5) Vigorous exercise
6) Patients who consume excessive alcohol
WARNINGS

8. All available DPP-4 inhibitors are offered as a once-daily dose,
so the unique once a week dosing of Wedica (Trelagliptin) is
not only innovative, but it is also exciting.
4 and 12 fold more potent than Alogliptin and Sitagliptin
 Lesser hypoglycemic events
Once in a week dosing ensures a significant efficacy

9. Study

11. Glucagon is a peptide hormone, produced by alpha cells of the pancreas. It
works to raise the concentration of glucose in the bloodstream.
Incretins are a group of metabolic hormones that stimulate a decrease in
blood glucose levels. They also inhibit glucagon release from the alpha cells of
the islets of Langerhans.
DPP-4 plays a major role in glucose metabolism. It is responsible for the
degradation of incretins and increase blood glucose level.
Important Terms

12. Target Doctors
•Diabetologist/Endocrinologist
•General Physician
Product Positioning
•Type 2 Diabetes

13. Thank
You!www.wedica.com.bd